179 related articles for article (PubMed ID: 37005236)
41. Computational Fluid Dynamics (CFD) Simulations of Spray Drying: Linking Drying Parameters with Experimental Aerosolization Performance.
Longest PW; Farkas D; Hassan A; Hindle M
Pharm Res; 2020 May; 37(6):101. PubMed ID: 32440940
[TBL] [Abstract][Full Text] [Related]
42. Sodium hyaluronate dry powder inhalation in combination with sodium cromoglycate prepared using optimized spray drying conditions.
Yildiz Türkyilmaz G; Özdokur KV; Alparslan L; Karasulu E
Pharm Dev Technol; 2023 Feb; 28(2):240-247. PubMed ID: 36730066
[TBL] [Abstract][Full Text] [Related]
43. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder.
Cai X; Yang Y; Xie X; Yu F; Yang Y; Yang Z; Zhang T; Mei X
Drug Deliv; 2016 Jul; 23(6):1962-71. PubMed ID: 26066037
[TBL] [Abstract][Full Text] [Related]
44. Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler:
Sahastrabudhe H; Kenjale P; Pokharkar V
Curr Drug Deliv; 2020; 17(8):703-710. PubMed ID: 32472998
[TBL] [Abstract][Full Text] [Related]
45. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
[TBL] [Abstract][Full Text] [Related]
46. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
47. Development of Biodegradable Polycation-Based Inhalable Dry Gene Powders by Spray Freeze Drying.
Okuda T; Suzuki Y; Kobayashi Y; Ishii T; Uchida S; Itaka K; Kataoka K; Okamoto H
Pharmaceutics; 2015 Aug; 7(3):233-54. PubMed ID: 26343708
[TBL] [Abstract][Full Text] [Related]
48. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
[TBL] [Abstract][Full Text] [Related]
49. Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury.
Liang D; Wang W; Chen G; Li J; Dou G; Gan H; Han P; Du L; Gu R
Molecules; 2023 May; 28(11):. PubMed ID: 37298919
[TBL] [Abstract][Full Text] [Related]
50. The effect of excipients on the stability and aerosol performance of salmon calcitonin dry powder inhalers prepared via the spray freeze drying process.
Poursina N; Vatanara A; Rouini MR; Gilani K; Najafabadi AR
Acta Pharm; 2016 Jun; 66(2):207-18. PubMed ID: 27279064
[TBL] [Abstract][Full Text] [Related]
51. Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology.
Tse JY; Kadota K; Imakubo T; Uchiyama H; Tozuka Y
Eur J Pharm Sci; 2021 Jan; 156():105600. PubMed ID: 33075466
[TBL] [Abstract][Full Text] [Related]
52. Large porous particles for respiratory drug delivery. Glycine-based formulations.
Ogienko AG; Bogdanova EG; Trofimov NA; Myz SA; Ogienko AA; Kolesov BA; Yunoshev AS; Zubikov NV; Manakov AY; Boldyrev VV; Boldyreva EV
Eur J Pharm Sci; 2017 Dec; 110():148-156. PubMed ID: 28479348
[TBL] [Abstract][Full Text] [Related]
53. Intranasal delivery of thin-film freeze-dried monoclonal antibodies using a powder nasal spray system.
Yu YS; Xu H; AboulFotouh K; Williams G; Suman J; Sahakijpijarn S; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2024 Mar; 653():123892. PubMed ID: 38350499
[TBL] [Abstract][Full Text] [Related]
54. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
[TBL] [Abstract][Full Text] [Related]
55. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
56. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
57. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide.
Qiu Y; Man RCH; Liao Q; Kung KLK; Chow MYT; Lam JKW
J Control Release; 2019 Nov; 314():102-115. PubMed ID: 31629037
[TBL] [Abstract][Full Text] [Related]
58. Micro-fluidic Spray Freeze Dried Ciprofloxacin Hydrochloride-Embedded Dry Powder for Inhalation.
Chen Y; Yan S; Zhang S; Yin Q; Chen XD; Wu WD
AAPS PharmSciTech; 2022 Aug; 23(6):211. PubMed ID: 35915199
[TBL] [Abstract][Full Text] [Related]
59. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
[TBL] [Abstract][Full Text] [Related]
60. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
